Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TTNP Mar 21st Adcom & s/b overwhelmingly positive & one sided imo....
TTNP added 5k $1.70
TTNP seller maybe getting close to end watch for vol flush & BTW glad the support TTNP has had is making this tard sell them off on the cheap...GLTA & make $$$$$$$$$$$
DARA nice basing action last week & Lion members picking it up as well. S/b good back to $1.20's
BGMD ??? big drop
Shreya sellers do so for many reasons & with such a large stake perhaps they want to take some risk off with a high % profit in the bank. Again don't know if they have been getting redemption's from their investors & need capital or a slew of other reasons. The bigger point is the strong support & accumulation taking place alongside this seller.... Will set us up for new highs into adcom imo.... GLTY & make $$$$$$$$$$$$
TTNP disclosing royalty rates higher then anticipated imo 15 to 22% very nice. Many long time holders felt since rates were not disclosed that they were in the area of tiered starting at 10% up to 15%. All in all some more good news now all we need is this warrant seller to finish so TTNP can head back to new highs GLTA & make $$$$$$$$$$$
TTNP disclosing royalty rates higher then anticipated imo 15 to 22% very nice. Many long time holders felt since rates were not disclosed that they were in the area of tiered starting at 10% up to 15%. All in all some more good news now all we need is this warrant seller to finish so TTNP can head back to new highs GLTA & make $$$$$$$$$$$
The support has been excellent & seller orderly although surprised he wont take a break a few hours a day geez....
Also CEO & Director purchased 75K shares at $1.50 a share old options they exercised but nice seeing insiders put their money on the line with us...Form 4's out this a.m.
Kei I'm sure it's a warrant holder getting out before FDA decision. Probably doesn't want the risk of holding so many shares & not be able to get out.
TTNP 2 insider form 4's filed as CEO & director exercised 75K shares at $1.50 a share....
TTNP nice near term catalyst now coming & will lead to run in April approval nice news....
ALXA news out receives marketing authorization for Adasue in European Union
NURO for the traders in the room did a 1 for 6 reverse has new Jan 2013 launch of pain product & over $4 in cash....low floater & reverse splits have gone nuts last few months for a TRADE..... CALI CBMX ROSG BOSC etc...
Don't believe those warrants are exercised as in filing there is a footnote stating
Comprised of warrants to purchase an aggregate of 6,588,234 shares of common stock held by Deerfield Special Situations Fund, L.P., Deerfield Special Situations International Master Fund, L.P., Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P., of which Deerfield Mgmt, L.P. is the general partner.
TTNP lol funny how Adam F from street always poo poo's small co.s in this case talking down TTNP commercial success against generics ???? There are NO generics on the market & Reckitt pulling all tablet forms off the market... the timing couldn't be better for TTNP to roll out a far better compliance option for a compliance problem treatment... Also dont forget the big time PR co. they hired to help with commercial roll out...
TTNP nice First Eagle owns 7.44 Million shares or 9.9% of total shares out...Wont be the last 13G filed ...
TTNP of course we all understand that no biotech is a sure thing but the chances of TTNP getting a CRL is slim to none imo...
Besides Priority Review which increases FDA approval rates to 75% TTNP submitted their NDA under a 505b application as the drug buprenorphine has been approved & in use since 2003, both safe & effective. Besides that has become the gold standard in opioid abuse treatment with a 58% CAGR & sales topping 1.4 Billion $$$$ a year.....couple both together gives TTNP a 90% + approval chance again imo... GLTY & make $$$$$$$$$$
TTNP DD you may find some of these links helpful BTW TTNP PR'd the PDUFA on Jan 2nd under Priority review accepted by FDA
Jan 7th Investor Presentation Note Nasdaq Up listing for early 2013
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001193125%2D13%2D004375%2Etxt&FilePath=%5C2013%5C01%5C07%5C&CoName=TITAN+PHARMACEUTICALS+INC&FormType=8%2DK&RcvdDate=1%2F7%2F2013&pdf=
Analyst Jason Napodano, CFA
http://bionapcfa.blogspot.com/search/label/Titan%20Pharma
priority review press release
http://finance.yahoo.com/news/probuphine-r-receives-fda-priority-120000404.html
Titan's partner deal press release note the 75 Million dollars pledged by partner for commercial roll out of Probuphine.
http://finance.yahoo.com/news/titan-pharmaceuticals-licenses-exclusive-probuphine-120000246.html
Pre partner analyst article naming TTNP & reasons for buying with $4.00 target.
http://seekingalpha.com/article/1064451-do-you-have-the-guts-to-take-on-cutting-edge-biotech-like-this-vc?source=yahoo
A Wall street journal article on opioid addiction & Titans treatment option
http://online.wsj.com/article/SB10001424052702303684004577506983158087406.html?KEYWORDS=titan#articleTabs%3Darticle
TTNP has had no adcom date issued only April 30th PDUFA ... If an adcom date were to be issued most likely would be late March....
TTNP added $1.97 as oversold & just above big support area...will add larger in $1.80's if it goes there...GLTA & make $$$$$$$
TTNP my read Sheff is this adds to their shareholder equity as needed to satisfy their Nasdaq up listing requirements .... They owe Deerfield 10 million I believe so exercising by applying exercise price towards debt increases shareholder equity...Imo this is leading into TTNP's public statement about up listing onto Nasdaq & will accelerate this process... I talked to CEO & was a major goal for early 2013
TTNP agreed nice needed pullback cleared out some profit takers allowed some new money to get in.... Will attack new 52 week Hi's again soon imo.... GLTA & make $$$$$$$$
TTNP agreed grabbed a bunch below $2.10... needed a healthy breather as posted TTNP basically doubled from $1.20 to $2.50 with no pullback only a consolidation pause in $1.80's ... Just my opinion $2 holds & will attack new highs before March Adcom... GLTA & make $$$$$$$$$$$$
TTNP been an absolute beast since breakout from $1.80's in fact from $1.20's to $1.80's consolidated perfectly then had next leg up... Wonder if & what point TTNP pulls back even a little lol...GLTA & make $$$$$$$$
TTNP interesting opioid abuse article.
http://americannewsreport.com/nationalpainreport/sharp-rise-in-suboxone-emergency-room-visits-8818470.html
Sharp Rise in Suboxone Emergency Room Visits
January 31st, 2013 by Pat Anson, Editor
A medication increasingly being used to treat addiction to opioid drugs – both legal and illegal – is sending ten times as many people to hospital emergency rooms as it did a few years ago.
Buprenorphine, which is more widely known under the brand name Suboxone, was involved in 30,135 emergency room visits in 2010, up from 3,161 visits in 2005, according to a report by the Substance Abuse and Mental Health Services Administration (SAMHSA). Over half of the hospitalizations were for non-medical use of buprenorphine – with some users taking the drug to get high.
“The buprenorphine in these visits may have been misused or abused, either for psychoactive effects or in an attempt to self-treat for opioid dependence,” the SAMHSA report said.
suboxonepicBuprenophine is an opioid that was approved as a treatment for opioid addiction in the U.S. in 2002. The use of the drug has grown significantly since its introduction. In 2005, over 5,000 physicians prescribed buprenorphine to 100,000 patients. By 2010, over 18,000 doctors were prescribing the drug to more than 800,000 patients.
Most of the buprenophine used to treat opioid addiction is made by Reckitt Benckiser, a British pharmaceutical company that combines buprenorphine with naloxone to make Suboxone. The two drugs are combined to help wean addicts not only off of illegal drugs like heroin and cocaine, but prescription opioid medicines such as Vicodin, OxyContin, oxycodone, and hydrocodone. Naloxone is added to Suboxone to block opioid receptors in the brain and central nervous system.
Reckitt recently started taking its tablet versions of Suboxone off the U.S. market, replacing them with a film version that dissolves under the tongue. The company says the film is less likely to be swallowed accidentally by children.
According to Drugs.com, Suboxone is the 28th top selling drug in the U.S. with nearly $1.4 billion in sales annually. Over three million Americans with opioid dependence have been treated with Suboxone.
Although it was developed as a “safe” way to wean addicts off opioids, some health officials are worried about the growing use and misuse of buprenorphine.
“Buprenorphine use can be risky for individuals who are not opioid dependent because its effects are similar to other opioids (although usually more mild), leading to injuries and other health consequences,” the SAMHSA report says.
“I’m not at all surprised to see that non-medical users are winding up in emergency rooms,” says Andrew Kolodny, MD, chairman of the Department of Psychiatry at Maimonides Medical Center and president of Physicians for Responsible Opioid Prescribing (PROP). Kolodny has been a leading advocate of Suboxone to treat addicts.
“Buprenorphine works differently from other opioids, so the risk of an overdose death is much lower. But if used improperly, by someone who has other opioids in their blood stream, it’s use can precipitate a powerful withdrawal reaction that makes someone feel like they’re going to die,” Kolodny wrote in an email to National Pain Report.
“Although these reports concern me, I would be much more concerned if black-market buprenorphine use was leading to new cases of opioid addiction and if its use was causing a rise in overdose deaths, but fortunately this does not seem to be the case,” Kolodny said. “We need to do a much better job of expanding access to treatment. If there was better access to doctors who know how to prescribe it responsibly, I think we’d see less people buying it on the street.”
In a recent report published in the Journal of Addictive Diseases, the Center for Substance Abuse Research (CESAR) at the University of Maryland warned “there may be an epidemic of buprenorphine misuse emerging across the U.S.” Researchers said addicts were smuggling buprenorphine into jails and the drug’s street value was growing because it doesn’t show up in drug tests.
“The true magnitude and scope of buprenorphine diversion, misuse, and adverse consequences is unknown because current epidemiologic measures do not systematically monitor buprenorphine,” CESAR warned in a December, 2012 newsletter. “Similarly, buprenorphine-related deaths are not accurately tracked because medical examiners and coroners do not routinely test for the drug.”
TTNP interesting opioid abuse article.
http://americannewsreport.com/nationalpainreport/sharp-rise-in-suboxone-emergency-room-visits-8818470.html
Sharp Rise in Suboxone Emergency Room Visits
January 31st, 2013 by Pat Anson, Editor
A medication increasingly being used to treat addiction to opioid drugs – both legal and illegal – is sending ten times as many people to hospital emergency rooms as it did a few years ago.
Buprenorphine, which is more widely known under the brand name Suboxone, was involved in 30,135 emergency room visits in 2010, up from 3,161 visits in 2005, according to a report by the Substance Abuse and Mental Health Services Administration (SAMHSA). Over half of the hospitalizations were for non-medical use of buprenorphine – with some users taking the drug to get high.
“The buprenorphine in these visits may have been misused or abused, either for psychoactive effects or in an attempt to self-treat for opioid dependence,” the SAMHSA report said.
suboxonepicBuprenophine is an opioid that was approved as a treatment for opioid addiction in the U.S. in 2002. The use of the drug has grown significantly since its introduction. In 2005, over 5,000 physicians prescribed buprenorphine to 100,000 patients. By 2010, over 18,000 doctors were prescribing the drug to more than 800,000 patients.
Most of the buprenophine used to treat opioid addiction is made by Reckitt Benckiser, a British pharmaceutical company that combines buprenorphine with naloxone to make Suboxone. The two drugs are combined to help wean addicts not only off of illegal drugs like heroin and cocaine, but prescription opioid medicines such as Vicodin, OxyContin, oxycodone, and hydrocodone. Naloxone is added to Suboxone to block opioid receptors in the brain and central nervous system.
Reckitt recently started taking its tablet versions of Suboxone off the U.S. market, replacing them with a film version that dissolves under the tongue. The company says the film is less likely to be swallowed accidentally by children.
According to Drugs.com, Suboxone is the 28th top selling drug in the U.S. with nearly $1.4 billion in sales annually. Over three million Americans with opioid dependence have been treated with Suboxone.
Although it was developed as a “safe” way to wean addicts off opioids, some health officials are worried about the growing use and misuse of buprenorphine.
“Buprenorphine use can be risky for individuals who are not opioid dependent because its effects are similar to other opioids (although usually more mild), leading to injuries and other health consequences,” the SAMHSA report says.
“I’m not at all surprised to see that non-medical users are winding up in emergency rooms,” says Andrew Kolodny, MD, chairman of the Department of Psychiatry at Maimonides Medical Center and president of Physicians for Responsible Opioid Prescribing (PROP). Kolodny has been a leading advocate of Suboxone to treat addicts.
“Buprenorphine works differently from other opioids, so the risk of an overdose death is much lower. But if used improperly, by someone who has other opioids in their blood stream, it’s use can precipitate a powerful withdrawal reaction that makes someone feel like they’re going to die,” Kolodny wrote in an email to National Pain Report.
“Although these reports concern me, I would be much more concerned if black-market buprenorphine use was leading to new cases of opioid addiction and if its use was causing a rise in overdose deaths, but fortunately this does not seem to be the case,” Kolodny said. “We need to do a much better job of expanding access to treatment. If there was better access to doctors who know how to prescribe it responsibly, I think we’d see less people buying it on the street.”
In a recent report published in the Journal of Addictive Diseases, the Center for Substance Abuse Research (CESAR) at the University of Maryland warned “there may be an epidemic of buprenorphine misuse emerging across the U.S.” Researchers said addicts were smuggling buprenorphine into jails and the drug’s street value was growing because it doesn’t show up in drug tests.
“The true magnitude and scope of buprenorphine diversion, misuse, and adverse consequences is unknown because current epidemiologic measures do not systematically monitor buprenorphine,” CESAR warned in a December, 2012 newsletter. “Similarly, buprenorphine-related deaths are not accurately tracked because medical examiners and coroners do not routinely test for the drug.”
There is no way we see dilution as Braeburn paying the costs to commercialize probuphine & currently has 22 million in cash with 50 million coming in late April plus warrant dollars of 15 million. So I see no reason TTNP would need to do an offering especially since they will partner outside the U.S. for probuphine in Europe & Asia collecting more upfront dollars & royalties....BTW read the sticky posts on top with some good info & nice read on Titan GLTA & make $$$$$$$$$$$$$$
Shreya let me start by saying this is all my opinion as no one here can predict with absolute certainty what will happen. As you are probably well aware of most Bio's will run up into adcom & if a positive outcome which I see happening easily for TTNP they should get a nice bump. I'm looking for $3+ area going into April PDUFA & can see $4 to $5 on FDA approval. The wildcard though could be media coverage, opioid abuse gets plenty of attention so a new way to combat & help addicts may lead to TV exposure with lots of new momo money pouring into TTNP. I like to keep it real & on the conservative side but believe at $2 TTNP is still undervalued GLTY & make $$$$$$$$$$$$$$
TTNP I have Never seen an Uplisting co. not go up from transferring from BB to Nasdaq as TTNP has publicly stated they are doing ...
TTNP nice finished HOD $2.10 New 52 Week Hi's again wont be the last time we write that about TTNP... being found imo...
TTNP nice Street.com article out this A.M. imo many more positive articles & even TV media attention will come on rampant opioid abuse a hot topic link
http://www.thestreet.com/story/11827815/1/titan-pharma-run-up-trade-into-march-fda-panel.html?puc=yahoo&cm_ven=YAHOO
TTNP here is Wall St Journal article on TTNP last summer.. I E-mailed the author updating him on Titan's status & probable FDA approval
http://online.wsj.com/article/SB10001424052702303684004577506983158087406.html?KEYWORDS=titan#articleTabs%3Darticle
TTNP nice Street.com article out imo many more positive articles & even TV media attention will come on rampant opioid abuse a hot topic link
http://www.thestreet.com/story/11827815/1/titan-pharma-run-up-trade-into-march-fda-panel.html?puc=yahoo&cm_ven=YAHOO
TTNP finished strong 210K & new large PR firm in place means TTNP hits the ground running upon approval & imo only means over 90% chance of FDA approval when coupling Priority review 75% chance PLUS 505B application with a 10 year + operating history & has become the gold standard knocking methadone to the curb... Easy approval for FDA board & $3.50 to $5 upon approval
New article out yesterday I expect lots of media buzz on TTNP in the weeks ahead as Opioid abuse gets lots of attention....
http://www.treatment4addiction.com/blog/addiction/the-potential-of-probuphine/
Enter Probuphine. This is a subdermal implant that is designed to deliver six months of buprenorphine hydrochloride (the active ingredient in Subutex and Suboxone) after one treatment. It is also the first drug of its kind to be developed, and it seems that the FDA has realized the need for effective treatment of addiction, as they have accepted Probuphine as a Priority Review drug and plan to move into action on April 30th, 2013.
Even though this is a novel development, this news gives me hope. Six months pass, the intensity of cravings decrease, withdrawals ease, and life goes on. Even if someone who has this treatment decides to use, he or she won’t be able to feel the effects, and the frustration of that will be discouraging. Best of all, that frustration will be linked to using!
How amazing that is: this drug is meant to provide relief from cravings and maintenance, and it can hopefully cause addicts to see the link between frustration and using! If that clarity aids people in achieving and maintaining sobriety, Probuphine can rightfully be called a “miracle drug” for the 21st century.
TTNP Jan 21 article it's starting as anything opioid addiction help will generate lots of media buzz imo ...
http://www.treatment4addiction.com/blog/addiction/the-potential-of-probuphine/
Enter Probuphine. This is a subdermal implant that is designed to deliver six months of buprenorphine hydrochloride (the active ingredient in Subutex and Suboxone) after one treatment. It is also the first drug of its kind to be developed, and it seems that the FDA has realized the need for effective treatment of addiction, as they have accepted Probuphine as a Priority Review drug and plan to move into action on April 30th, 2013.
Even though this is a novel development, this news gives me hope. Six months pass, the intensity of cravings decrease, withdrawals ease, and life goes on. Even if someone who has this treatment decides to use, he or she won’t be able to feel the effects, and the frustration of that will be discouraging. Best of all, that frustration will be linked to using!
How amazing that is: this drug is meant to provide relief from cravings and maintenance, and it can hopefully cause addicts to see the link between frustration and using! If that clarity aids people in achieving and maintaining sobriety, Probuphine can rightfully be called a “miracle drug” for the 21st century.
I see they now require a sub so here is full article out late Friday
MSL picked to support opioid dependence treatment
Virgil Dickson
January 18, 2013
NEW YORK: Braeburn Pharmaceuticals has hired MSLGroup to support the planning and launch of Probuphine, a subdermal implant for the maintenance treatment of opioid dependence in adult patients.
Earlier this month, the US Food and Drug Administration indicated that it would give the product's regulatory application an expedited review.
Jim Weinrebe, EVP at SchwartzMSL Boston, is leading work on the account. Beyond confirming the win, he could say little about the work the firm is doing on the account while the product is under review. Weinrebe said pitching for the business was a “substantial” endeavor.
The potential market for the product is up to 2.3 million people in the US, according to Titan Pharmaceuticals, which signed a license agreement with Braeburn last month. That represents the number of people who are addicted to opoids in America, according to Titan.
Titan expects to receive up to $50 million if Probuphone is approved by the FDA, and tens of millions of dollars more if regulatory milestones for extraneous indications like chronic pain are reached.
Apple Tree Partners, a life sciences venture capital firm, owns Braeburn Pharmaceuticals. Representatives from the company declined to comment on account.
In spring 2012, Retina Implant AG, a German developer of sub-retinal implants for partially sighted and blind patients, teamed with SchwartzMSL Boston to build buzz for its technology in the US.
TTNP late day news out as Braeburn hired MSL group with rollout & awareness big global company
http://www.prweekus.com/msl-picked-to-support-opioid-dependence-treatment/article/276555/